Lista de obras - Shakeel Modak - Dominio Público Uruguay

5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma

artículo científico publicado en 2012

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

artículo científico publicado en 2017

A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.

artículo científico publicado en 2009

A novel image-based system for risk stratification in patients with desmoplastic small round cell tumor.

artículo científico publicado en 2018

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors

artículo científico publicado en 2016

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

artículo científico publicado en 2017

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma

artículo científico publicado en 2016

Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma

artículo científico publicado en 2016

Acute pain relief after Mantram meditation in children with neuroblastoma undergoing anti-GD2 monoclonal antibody therapy.

artículo científico publicado en 2014

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study

scientific article published on 10 May 2018

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma

artículo científico publicado en 2013

Anti-GD2 immunotherapy for neuroblastoma.

artículo científico publicado en 2017

Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins

artículo científico publicado en 2002

Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy

artículo científico publicado en 2003

Antibody-based targeted radiation to pediatric tumors.

artículo científico publicado en 2005

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study

artículo científico publicado en 2016

Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging

artículo científico publicado en 2017

Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

artículo científico publicado en 2017

Biodistribution and dosimetry of (18)F-Meta Fluorobenzyl Guanidine (MFBG): A first-in-human PET-CT imaging study of patients with neuroendocrine malignancies.

artículo científico

Brain-sparing radiotherapy for neuroblastoma skull metastases

artículo científico publicado en 2008

Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma

artículo científico publicado en 2004

Central nervous system germ cell tumors.

artículo científico publicado en 1998

Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

artículo científico publicado en 2017

Desmoplastic small round cell tumor 20 years after its discovery

artículo científico publicado en 2015

Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma

artículo científico publicado en 2010

Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor

scientific article published on 01 December 2002

Dose-escalation is needed for gross disease in high-risk neuroblastoma.

artículo científico publicado en 2018

EPT-08A PHASE I STUDY OF SINGLE-AGENT PERIFOSINE FOR RECURRENT/REFRACTORY PEDIATRIC CNS AND SOLID TUMORS.

artículo científico publicado en 2016

Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine

artículo científico

Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.

artículo científico publicado en 2016

Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse

artículo científico publicado en 2017

Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma

artículo científico publicado en 2017

Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.

artículo científico publicado en 2016

Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.

artículo científico publicado en 2005

Germline SDHA mutations in children and adults with cancer

scientific article published on 01 August 2018

High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan

artículo científico publicado en 2011

High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy

artículo científico publicado en 2007

High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma

artículo científico publicado en 2010

Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial

artículo científico publicado en 2018

Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.

artículo científico publicado en 2009

Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma

artículo científico publicado en 2010

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

artículo científico publicado en 2006

Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy?

scientific article published on 16 May 2016

Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma

artículo científico publicado en 2014

Lack of early bevacizumab-related skeletal radiographic changes in children with neuroblastoma

scientific article published on 01 February 2009

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

artículo científico publicado en 2015

Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients

artículo científico publicado en 2006

Local Anesthesia With General Anesthesia for Pediatric Bone Marrow Procedures

scientific article published on 01 August 2019

Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma

artículo científico publicado en 2016

Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma.

artículo científico publicado en 2017

Long-term complications in survivors of advanced stage neuroblastoma

artículo científico publicado en 2005

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

artículo científico publicado en 2017

Management of desmoplastic small round cell tumor

artículo científico publicado en 2016

Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors

artículo científico publicado en 2001

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

artículo científico publicado en 2012

Myeloablative chemotherapy with autologous stem cell transplant for desmoplastic small round cell tumor

artículo científico publicado en 2015

Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience

artículo científico publicado en 2003

Norepinephrine Transporter as a Target for Imaging and Therapy.

artículo científico publicado en 2017

Nuclear war--doctor's responsibility

scientific article published on 01 May 1987

Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma

scientific article published on 01 May 2002

Osteochondroma in long-term survivors of high-risk neuroblastoma

artículo científico publicado en 2015

Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission

artículo científico publicado en 2014

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

artículo científico publicado en 2017

Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma

artículo científico publicado en 2011

Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti‐GD2 3F8 monoclonal antibody ⬇️

artículo científico publicado el 30 de abril de 2013

Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections

artículo científico publicado en 2010

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study

artículo científico publicado en 2015

Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

artículo científico publicado en 2018

Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9.

artículo científico publicado en 2005

Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide

artículo científico publicado en 2008

Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma

artículo científico publicado en 2009

Reduced toxicity with intensity modulated radiation therapy (IMRT) for desmoplastic small round cell tumor (DSRCT): an update on the whole abdominopelvic radiation therapy (WAP-RT) experience

artículo científico publicado en 2012

Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial

scientific article published on 11 February 2019

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma

artículo científico publicado en 2004

Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy.

artículo científico publicado en 2017

Results of multimodal treatment for desmoplastic small round cell tumors.

artículo científico publicado en 2005

Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan

artículo científico publicado en 2005

Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy

artículo científico publicado en 2019

Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass

artículo científico publicado en 2015

Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma.

artículo científico publicado en 2009

Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.

artículo científico publicado en 2004

Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.

artículo científico publicado en 2014

Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.

artículo científico publicado en 2011

Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors

artículo científico publicado en 2004

Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system

artículo científico publicado en 2006

Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma

artículo científico publicado en 2015

Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy

artículo científico publicado en 2008

Treatment and outcome of adult-onset neuroblastoma.

artículo científico publicado en 2018

Treatment of children with immune thrombocytopenic purpura: Are we closer to resolving the dilemma? ⬇️

artículo científico publicado el 1 de septiembre de 1998

Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification

artículo científico publicado en 2003

Updates in the treatment of neuroblastoma

artículo científico publicado el 1 de enero de 2011

When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?

artículo científico publicado en 2014

Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma

artículo científico publicado en 2010

Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.

artículo científico publicado en 2007

Lista de obras de Shakeel Modak

5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.

A novel image-based system for risk stratification in patients with desmoplastic small round cell tumor.

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma

Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma

Acute pain relief after Mantram meditation in children with neuroblastoma undergoing anti-GD2 monoclonal antibody therapy.

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma

Anti-GD2 immunotherapy for neuroblastoma.

Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins

Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy

Antibody-based targeted radiation to pediatric tumors.

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study

Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging

Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

Biodistribution and dosimetry of (18)F-Meta Fluorobenzyl Guanidine (MFBG): A first-in-human PET-CT imaging study of patients with neuroendocrine malignancies.

Brain-sparing radiotherapy for neuroblastoma skull metastases

Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma

Central nervous system germ cell tumors.

Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

Desmoplastic small round cell tumor 20 years after its discovery

Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma

Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor

Dose-escalation is needed for gross disease in high-risk neuroblastoma.

EPT-08A PHASE I STUDY OF SINGLE-AGENT PERIFOSINE FOR RECURRENT/REFRACTORY PEDIATRIC CNS AND SOLID TUMORS.

Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine

Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.

Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse

Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma

Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.

Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.

Germline SDHA mutations in children and adults with cancer

High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan

High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy

High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma

Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial

Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.

Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy?

Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma

Lack of early bevacizumab-related skeletal radiographic changes in children with neuroblastoma

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients

Local Anesthesia With General Anesthesia for Pediatric Bone Marrow Procedures

Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma

Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma.

Long-term complications in survivors of advanced stage neuroblastoma

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

Management of desmoplastic small round cell tumor

Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

Myeloablative chemotherapy with autologous stem cell transplant for desmoplastic small round cell tumor

Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience

Norepinephrine Transporter as a Target for Imaging and Therapy.

Nuclear war--doctor's responsibility

Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma

Osteochondroma in long-term survivors of high-risk neuroblastoma

Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma

Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti‐GD2 3F8 monoclonal antibody ⬇️

Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study

Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9.

Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide

Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma

Reduced toxicity with intensity modulated radiation therapy (IMRT) for desmoplastic small round cell tumor (DSRCT): an update on the whole abdominopelvic radiation therapy (WAP-RT) experience

Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma

Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy.

Results of multimodal treatment for desmoplastic small round cell tumors.

Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan

Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy

Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass